Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders. It applies a precision-medicine approach, including genetically informed drug design, to conditions such as epilepsy and other neurological and psychiatric diseases. Its pipeline centers on small-molecule and antisense candidates rather than commercial products, reflecting an R&D-focused model aimed at hard-to-treat CNS indications.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -69.3 | — |
| Q2 2025 | 0 | — | -71.1 | — |
| Q3 2025 | 0 | — | -73.9 | — |
| Q4 2025 | 0 | — | -88.9 | — |
| Q1 2026 | 0 | — | -92.6 | — |
| Q2 2026 | 0 | — | -83.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Rush Enterprises, Inc. (RUSHB), Amneal Pharmaceuticals, Inc. (AMRX), Victory Capital Holdings, Inc. (VCTR), Duolingo, Inc. (DUOL), Navan, Inc. (NAVN), SSR Mining Inc. (SSRM)